东瑞制药(02348)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02348 东瑞制药

未开盘 06-01 14:47:17

1.050

+0.000

0.00%

最高1.050	最低1.050	成交量8,000
今开1.050	昨收1.050	日振幅0.00%
总市值15.79亿	流通市值15.79亿	总股本15.04亿
成交额8,400	换手率0.00%	流通股本15.04亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02348","market":"HK","secType":"STK","nameCN":"东瑞制药","latestPrice":1.05,"timestamp":1780296437563,"preClose":1.05,"halted":0,"volume":8000,"delay":0,"changeRate":0,"floatShares":1504000000,"shares":1504000000,"eps":0.16220529219964888,"marketStatus":"未开盘","change":0,"latestTime":"06-01 14:47:17","open":1.05,"high":1.05,"low":1.05,"amount":8400,"amplitude":0,"askPrice":1.07,"askSize":12000,"bidPrice":1.05,"bidSize":200000,"shortable":0,"etf":0,"ttmEps":0.16220529219964888,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780363800000},"marketStatusCode":0,"adr":0,"listingDate":1057852800000,"exchange":"SEHK","adjPreClose":1.05,"dividendRate":0.06,"openAndCloseTimeList":[[1780277400000,1780286400000],[1780290000000,1780300800000]],"volumeRatio":0.03078,"lotSize":4000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02348","defaultTab":"news","newsList":[{"id":"1132753574","title":"东瑞制药子公司盐酸曲唑酮片50毫克与100毫克获中国批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1132753574","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132753574?lang=zh_cn&edition=full","pubTime":"2026-05-29 16:43","pubTimestamp":1780044188,"startTime":"0","endTime":"0","summary":"东瑞制药（控股）有限公司旗下子公司，已成功获得中国监管部门对盐酸曲唑酮片50毫克及100毫克两种规格的生产批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639286026","title":"东瑞制药(02348)：盐酸曲唑酮片50毫克及100毫克获得药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2639286026","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639286026?lang=zh_cn&edition=full","pubTime":"2026-05-29 16:42","pubTimestamp":1780044179,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东瑞制药(02348)发布公告，集团附属公司福建东瑞制药有限公司取得中国国家药品监督管理局有关盐酸曲唑酮片50毫克及100毫克的药品生产注册批件，属于化学药品第3类，视同通过一致性评价。此产品适用于抑郁症的治疗，对伴有或不伴有焦虑的患者均适用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447735.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东瑞制药(02348)：盐酸曲唑酮片50毫克及100毫克获得药品生产注册批件","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02348","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638750834","title":"东瑞制药(02348)附属取得琥珀酸曲格列汀片50毫克及100毫克的药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2638750834","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638750834?lang=zh_cn&edition=full","pubTime":"2026-05-27 16:32","pubTimestamp":1779870755,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东瑞制药(02348)公布，集团的附属公司苏州东瑞制药有限公司是国内第二家企业取得中国国家药品监督管理局有关琥珀酸曲格列汀片50毫克及100毫克的药品生产注册批件，属于化学药品第3类，视同通过一致性评价。此产品为口服降糖周制剂，可单药治疗用于2型糖尿病成人患者改善血糖控制。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02348","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187103365","title":"东瑞制药4月股份变动月报：股本增至1,503,723,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1187103365","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187103365?lang=zh_cn&edition=full","pubTime":"2026-05-05 16:10","pubTimestamp":1777968656,"startTime":"0","endTime":"0","summary":"2026年5月5日，东瑞制药公布截至2026年4月30日的股份变动月报。公告显示，公司本月法定注册股本维持为20,000,000,000股普通股，每股面值0.05港元，总额1,000,000,000港元，较上月无变化。报告期内，公司已发行股份由上月底的1,503,605,000股增加118,000股至1,503,723,000股，主要因“2013购股权计划”下的期权行使所致；本月行使期权筹资金额为106,200港元。截至4月30日，公司库藏股份数目仍为零，同时本月内无任何购回及注销股份活动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128120013","title":"东瑞制药授予董事股份购回授权，规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1128120013","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128120013?lang=zh_cn&edition=full","pubTime":"2026-04-23 19:12","pubTimestamp":1776942723,"startTime":"0","endTime":"0","summary":"东瑞制药(控股)有限公司于4月24日公告，董事会拟于即将召开的股东周年大会上寻求授权购回最多相当于公司已发行股本10%的股份。据披露，截至2026年4月20日，公司已发行股份总数为1,503,723,000股，如获批准，最多可回购150,372,300股。该购回计划将遵循开曼群岛适用法例及香港联交所上市规则进行，购回所需资金来自溢利或依法可动用的资本金。东瑞制药计划于5月22日召开股东周年大会，审议有关股份购回授权及其他事项。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"东瑞制药授予董事股份购回授权，规模达已发行股本一成","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154507051","title":"东瑞制药2025年报：收入同比增16.1%至12.31亿元，非经常性项目拖累净利下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=1154507051","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154507051?lang=zh_cn&edition=full","pubTime":"2026-04-23 19:11","pubTimestamp":1776942673,"startTime":"0","endTime":"0","summary":"东瑞制药于本报告期实现收入约人民币12.31亿元，同比增长约16.1%。扣除一次性处置股权及相关投资损失等非经常性影响后，经营利润较上一年度有所增长，但归属于母公司拥有人应占溢利仍录得约人民币2.14亿元，同比下降约62.1%。董事会建议派发末期股息每股港币0.048元，合计约港币7,217.1万元，使本期股息支付率上升至约39.3%。公司聘请安永会计师事务所担任年度核数师，核数师意见认为财务报表在所有重大方面均能公平反映公司的财务状况与经营成果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"东瑞制药2025年报：收入同比增16.1%至12.31亿元，非经常性项目拖累净利下滑","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193151961","title":"东瑞制药2026年3月股份变动月报表，股本微增48,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1193151961","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193151961?lang=zh_cn&edition=full","pubTime":"2026-04-02 16:35","pubTimestamp":1775118952,"startTime":"0","endTime":"0","summary":"2026年4月2日，东瑞制药(控股)有限公司披露截至2026年3月31日的3月股份变动月报表。公告显示，公司于报告期末的法定股本维持在20,000,000,000股，每股面值0.05港元，总额1,000,000,000港元，较上个月无变化。公告确认公司公众持股量符合相关要求，且月内并无新增库藏股或回购注销事项。期权与激励计划方面，2026年3月共有48,000股因行使2013购股权计划而发行，截至月末该计划剩余8,580,000份未行使期权。本月行使期权共筹资43,200港元。2023购股权计划的期权数量整体维持不变。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623358231","title":"东瑞制药(02348.HK)2025年度净亏损降62.1%至2.14亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2623358231","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623358231?lang=zh_cn&edition=full","pubTime":"2026-03-29 16:37","pubTimestamp":1774773421,"startTime":"0","endTime":"0","summary":"格隆汇3月29日丨东瑞制药(02348.HK)公布年度业绩，2024年度，集团年度录得收入约人民币12.31亿元，较二2024年增加约16.1%。母公司拥有人应占溢利约人民币2.14亿元，比2024年减少62.1%。因2024年母公司拥有人应占溢利含出售于集团账面值为零元的35%康融东方股权录得净收益约人民币2.78亿元所致；如撇除以上非经常性溢利约人民币3.67亿元及出售股权前需分担的康融东方亏损人民币369.6万元因素，2024年母公司拥有人经营性溢利为人民币2.02亿元，则2025年较2024年增加6.1%。拟派末期息每股0.048港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260329/32108908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1191","02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622536871","title":"东瑞制药(02348)发布年度业绩 股东应占溢利2.14亿元，同比减少62.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622536871","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622536871?lang=zh_cn&edition=full","pubTime":"2026-03-28 00:54","pubTimestamp":1774630493,"startTime":"0","endTime":"0","summary":"东瑞制药(02348)发布截至2025年12月31日止年度业绩，该集团取得收入12.31亿元(人民币，下同)，同比增长16.1%;母公司拥有人应占溢利2.14亿元，同比减少62.1%;每股基本盈利0.14元。拟派发末期股息每股为港币0.048元","market":"fut","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_25.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_25.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421206.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1191","02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176608373","title":"东瑞制药将于2026年6月12日派发末期股息每股0.048港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176608373","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176608373?lang=zh_cn&edition=full","pubTime":"2026-03-27 23:03","pubTimestamp":1774623813,"startTime":"0","endTime":"0","summary":"东瑞制药(02348)于2026年3月27日公布，截至2025年12月31日止年度董事会决议派发末期股息，每股0.048港元，须于股东批准后发放。\n股息分派要点：\n1. 股息类型：末期股息  \n2. 股息金额：每股0.048港元  \n3. 股东批准日期：2026年5月22日  \n4. 除净日：2026年5月27日  \n5. 最后过户登记日：2026年5月28日16:30  \n6. 暂停办理股份过户登记：2026年5月29日至2026年6月1日  \n7. 记录日期：2026年6月1日  \n8. 派息日：2026年6月12日","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619319501","title":"东瑞制药(02348.HK)3月27日举行董事会会议批准刊发全年业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2619319501","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619319501?lang=zh_cn&edition=full","pubTime":"2026-03-13 18:27","pubTimestamp":1773397622,"startTime":"0","endTime":"0","summary":"格隆汇3月13日丨东瑞制药(02348.HK)宣布，公司董事会会议将于2026年3月27日(星期五)举行，藉以(其中包括)批准刊发公司及其附属公司截至2025年12月31日止年度的全年业绩公告，以及考虑建议派发末期股息(如有)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260313/32067121.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1191","02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192330771","title":"东瑞制药（控股）（02348）2026年2月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1192330771","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192330771?lang=zh_cn&edition=full","pubTime":"2026-03-03 18:06","pubTimestamp":1772532395,"startTime":"0","endTime":"0","summary":"东瑞制药（控股）有限公司于2026年3月3日发布截至2026年2月28日的股份变动月报表。报告显示，公司注册股本与已发行股份数均保持不变，整体股本在当月未出现新增发行、购回或注销等变动。报告期末已发行股份数为1,503,557,000股，库藏股份数为0股，均与上月保持一致。公司同时披露了2013购股权计划与2023购股权计划的相关数据，当月并未因期权行使或转让而新增发行股份。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129451193","title":"东瑞制药（控股）（2348）1月股份变动月报：增发200,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1129451193","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129451193?lang=zh_cn&edition=full","pubTime":"2026-02-03 16:12","pubTimestamp":1770106347,"startTime":"0","endTime":"0","summary":"东瑞制药（控股）有限公司于2026年2月3日披露2026年1月股份变动月报表，报告期截至2026年1月31日。公司注册股本维持在20,000,000,000股，面值为每股0.05港元，总额1,000,000,000港元，未见变动。\\n\\n月报显示，公司已发行股份由上月底的1,503,357,000股增至1,503,557,000股，增加200,000股。公司当月未呈列任何库藏股或回购注销安排，公共持股量亦符合相关规定。截至1月底，期权相关股份数目及面值安排均已获得公司董事会正式授权。该月报由公司秘书彭洁玲签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605282135","title":"东瑞制药01月23日主力净流出26.0万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2605282135","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605282135?lang=zh_cn&edition=full","pubTime":"2026-01-23 16:15","pubTimestamp":1769156111,"startTime":"0","endTime":"0","summary":"01月23日，东瑞制药股价收平报1.17元，成交金额63.7万元，换手率0.04%，振幅0.85%，量比1.23。东瑞制药今日主力资金净流出26.0万元，上一交易日主力净流出0万元。该股近5个交易日下跌2.50%，主力资金累计净流出26.0万元；近20日主力资金累计净流出26.0万元，其中净流出天数为1日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260123161557a44d82af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260123161557a44d82af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02348","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155715444","title":"东瑞制药（控股）（02348）公布2025年12月月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1155715444","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155715444?lang=zh_cn&edition=full","pubTime":"2026-01-06 17:12","pubTimestamp":1767690773,"startTime":"0","endTime":"0","summary":"东瑞制药（控股）有限公司于2026年1月6日发布截至2025年12月31日的月报表。报告显示，公司法定股本维持在20,000,000,000股，对应总额HKD 1,000,000,000，未发生变动。公司已发行普通股于期末为1,503,357,000股，与上月保持一致，无购回或注销活动，也无新增发行及库藏股变动。截至2025年12月31日，公司股本结构保持稳定，合计已发行股份总数为1,503,357,000股。公司确认遵守香港联合交易所有限公司《上市规则》及相关法律规定，本次月报表由公司秘书彭洁玲签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02348"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589382961","title":"36个品种拟进院，独家品种占比超35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589382961","media":"赛柏蓝","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589382961?lang=zh_cn&edition=full","pubTime":"2025-12-06 19:21","pubTimestamp":1765020078,"startTime":"0","endTime":"0","summary":"36款拟引进的新药中，独家品种占比超35%，涉及复方鳖甲软肝片、地达西尼胶囊、递法明片等潜力品种；另有12个国采品种在列，石药集团、华海药业、倍特药业等集采中选企业优势十足。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251206192444a7278966&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251206192444a7278966&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","01093","02348","06887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2492512419","title":"主席李其玲增持东瑞制药(02348)18.4万股 每股作价1.2港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492512419","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492512419?lang=zh_cn&edition=full","pubTime":"2024-12-17 20:05","pubTimestamp":1734437100,"startTime":"0","endTime":"0","summary":"香港联交所最新资料显示，12月13日，主席李其玲增持东瑞制药(02348)18.4万股，每股作价1.2港元，总金额为22.08万港元。增持后最新持股数目为7.08亿股，最新持股比例为47.14%。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-12-17/doc-inczurfi4699083.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02348","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2488988539","title":"主席李其玲增持东瑞制药(02348)8.8万股 每股作价约1.21港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488988539","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488988539?lang=zh_cn&edition=full","pubTime":"2024-12-03 16:26","pubTimestamp":1733214376,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，11月29日，主席李其玲增持东瑞制药(02348)8.8万股，每股作价1.2132港元，总金额为10.68万港元。增持后最新持股数目为7.07亿股，持股比例为47.08%。本交易涉及其他关联方：熊融礼。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219621.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02348","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2480327046","title":"东瑞制药盘中异动 快速上涨7.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480327046","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480327046?lang=zh_cn&edition=full","pubTime":"2024-11-04 15:42","pubTimestamp":1730706161,"startTime":"0","endTime":"0","summary":"2024年11月04日临近收盘15时42分，东瑞制药股票出现波动，股价急速上涨7.26%。截至发稿，该股报1.330港元/股，成交量7.6万股，换手率0.01%，振幅8.06%。资金方面，该股资金流入5320港元，流出7.932万港元。东瑞制药股票所在的药品行业中，整体涨幅为0.46%。其相关个股中，信达生物、中国医疗集团、海王英特龙涨幅较大，振幅较大的相关个股有顺腾国际控股、兴科蓉医药、三爱健康集团，振幅分别为22.22%、18.75%、10.94%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104154241a2141202&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104154241a2141202&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02348","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2479247918","title":"东瑞制药股价上涨11.20% 市值涨2.34亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479247918","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479247918?lang=zh_cn&edition=full","pubTime":"2024-10-30 14:58","pubTimestamp":1730271483,"startTime":"0","endTime":"0","summary":"2024年10月30日下午盘14时58分，东瑞制药股票出现异动，股价大幅上涨11.20%。截至发稿，该股报1.390港元/股，成交量3.6万股，换手率0.00%，振幅12.00%。资金方面，该股资金流入5560港元，流出3.972万港元。东瑞制药股票所在的药品行业中，整体跌幅为0.56%。其相关个股中，开拓药业-B、艾美疫苗、白花油涨幅较大，振幅较大的相关个股有翰森制药、泰凌医药、德琪医药-B，振幅分别为12.52%、12.12%、11.76%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030145803ab81ead2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030145803ab81ead2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02348"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dawnrays.com","stockEarnings":[{"period":"1week","weight":-0.0113},{"period":"1month","weight":-0.0287},{"period":"3month","weight":-0.0617},{"period":"6month","weight":-0.1071},{"period":"1year","weight":-0.0885},{"period":"ytd","weight":-0.1003}],"compareEarnings":[{"period":"1week","weight":-0.0081},{"period":"1month","weight":-0.0147},{"period":"3month","weight":-0.0144},{"period":"6month","weight":-0.0141},{"period":"1year","weight":0.0905},{"period":"ytd","weight":-0.0091}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"东瑞制药（控股）有限公司是一家主要从事非专利药物的开发、制造及销售业务的投资控股公司。该公司通过两个部门运营业务。成药分部从事制造及销售成药。中间体及原料药分部从事制造及销售中间体及原料药。","yearOnYearQuotes":[{"month":1,"riseRate":0.478261,"avgChangeRate":0.000714},{"month":2,"riseRate":0.478261,"avgChangeRate":-0.003766},{"month":3,"riseRate":0.478261,"avgChangeRate":0.017595},{"month":4,"riseRate":0.695652,"avgChangeRate":0.037646},{"month":5,"riseRate":0.478261,"avgChangeRate":0.016893},{"month":6,"riseRate":0.565217,"avgChangeRate":0.008304},{"month":7,"riseRate":0.545455,"avgChangeRate":0.018687},{"month":8,"riseRate":0.347826,"avgChangeRate":-0.017932},{"month":9,"riseRate":0.478261,"avgChangeRate":0.022113},{"month":10,"riseRate":0.434783,"avgChangeRate":-0.001342},{"month":11,"riseRate":0.565217,"avgChangeRate":0.035884},{"month":12,"riseRate":0.565217,"avgChangeRate":0.012599}],"exchange":"SEHK","name":"东瑞制药","nameEN":"DAWNRAYS PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东瑞制药(02348)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东瑞制药(02348)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东瑞制药,02348,东瑞制药股票,东瑞制药股票老虎,东瑞制药股票老虎国际,东瑞制药行情,东瑞制药股票行情,东瑞制药股价,东瑞制药股市,东瑞制药股票价格,东瑞制药股票交易,东瑞制药股票购买,东瑞制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东瑞制药(02348)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东瑞制药(02348)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}